Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials.
Thinzar MinStephen C BainPublished in: Expert opinion on emerging drugs (2023)
Teplizumab has demonstrated potential as a preventative agent for individuals at risk prior to the onset of overt dysglycemia. However, these agents are not without side effects, and there are uncertainties on long-term safety. Technological advances have led a substantial influence on quality of life of people suffering from T1DM. There remains variation in uptake of new technologies across the globe. Novel insulins (ultra-long acting), oral insulin, and inhaled insulin attempt to narrow the gap of unmet needs. Islet cell transplant is another exciting field, and stem cell therapy might have potential to provide unlimited supply of islet cells.
Keyphrases
- cell therapy
- type diabetes
- clinical trial
- stem cells
- glycemic control
- induced apoptosis
- mesenchymal stem cells
- single cell
- cystic fibrosis
- human health
- cell cycle arrest
- high resolution
- risk assessment
- metabolic syndrome
- randomized controlled trial
- cell proliferation
- signaling pathway
- endoplasmic reticulum stress
- oxidative stress
- cell death
- insulin resistance
- skeletal muscle
- adipose tissue
- study protocol
- placebo controlled